204 related articles for article (PubMed ID: 8620429)
1. Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies.
Spencer DI; Price MR; Tendler SJ; De Matteis CI; Stadie T; Hanisch FG
Cancer Lett; 1996 Feb; 100(1-2):11-5. PubMed ID: 8620429
[TBL] [Abstract][Full Text] [Related]
2. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
[TBL] [Abstract][Full Text] [Related]
4. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
[TBL] [Abstract][Full Text] [Related]
5. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
6. Epitope mapping of anti-MUC1 mucin protein core monoclonal antibodies.
Petrakou E; Murray A; Price MR
Tumour Biol; 1998; 19 Suppl 1():21-9. PubMed ID: 9422085
[TBL] [Abstract][Full Text] [Related]
7. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
8. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.
Price MR; Rye PD; Petrakou E; Murray A; Brady K; Imai S; Haga S; Kiyozuka Y; Schol D; Meulenbroek MF; Snijdewint FG; von Mensdorff-Pouilly S; Verstraeten RA; Kenemans P; Blockzjil A; Nilsson K; Nilsson O; Reddish M; Suresh MR; Koganty RR; Fortier S; Baronic L; Berg A; Longenecker MB; Hilgers J
Tumour Biol; 1998; 19 Suppl 1():1-20. PubMed ID: 9422084
[TBL] [Abstract][Full Text] [Related]
9. Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin.
Dai J; Allard WJ; Davis G; Yeung KK
Tumour Biol; 1998; 19 Suppl 1():100-10. PubMed ID: 9422094
[TBL] [Abstract][Full Text] [Related]
10. Structural effects of O-glycosylation on a 15-residue peptide from the mucin (MUC1) core protein.
Kirnarsky L; Prakash O; Vogen SM; Nomoto M; Hollingsworth MA; Sherman S
Biochemistry; 2000 Oct; 39(39):12076-82. PubMed ID: 11009623
[TBL] [Abstract][Full Text] [Related]
11. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.
Karsten U; Diotel C; Klich G; Paulsen H; Goletz S; Müller S; Hanisch FG
Cancer Res; 1998 Jun; 58(12):2541-9. PubMed ID: 9635576
[TBL] [Abstract][Full Text] [Related]
12. Discrimination of MUC1 mucins from other sialyl-Le(a)-carrying glycoproteins produced by colon carcinoma cells using a novel monoclonal antibody.
Baeckström D; Nilsson O; Price MR; Lindholm L; Hansson GC
Cancer Res; 1993 Feb; 53(4):755-61. PubMed ID: 7679050
[TBL] [Abstract][Full Text] [Related]
13. MUC1 and cancer.
Taylor-Papadimitriou J; Burchell J; Miles DW; Dalziel M
Biochim Biophys Acta; 1999 Oct; 1455(2-3):301-13. PubMed ID: 10571020
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats.
Hanisch FG; Stadie T; Bosslet K
Cancer Res; 1995 Sep; 55(18):4036-40. PubMed ID: 7545084
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies.
Reddish MA; Suresh MR; Koganty RR; Fortier S; Baronic L; Berg A; Longenecker BM
Tumour Biol; 1998; 19 Suppl 1():57-66. PubMed ID: 9422089
[TBL] [Abstract][Full Text] [Related]
16. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
17. Epitope characterization of MUC1 antibodies.
Blockzjil A; Nilsson K; Nilsson O
Tumour Biol; 1998; 19 Suppl 1():46-56. PubMed ID: 9422088
[TBL] [Abstract][Full Text] [Related]
18. Epitope expression on the breast epithelial mucin.
Ceriani RL; Peterson JA; Blank EW; Lamport DT
Breast Cancer Res Treat; 1992; 24(2):103-13. PubMed ID: 7680246
[TBL] [Abstract][Full Text] [Related]
19. MUC1 glycopeptide epitopes predicted by computational glycomics.
Song W; Delyria ES; Chen J; Huang W; Lee JS; Mittendorf EA; Ibrahim N; Radvanyi LG; Li Y; Lu H; Xu H; Shi Y; Wang LX; Ross JA; Rodrigues SP; Almeida IC; Yang X; Qu J; Schocker NS; Michael K; Zhou D
Int J Oncol; 2012 Dec; 41(6):1977-84. PubMed ID: 23023583
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a panel of monoclonal antibodies using GalNAc glycosylated peptides and recombinant MUC1.
Reis CA; Hassan H; Bennett EP; Clausen H
Tumour Biol; 1998; 19 Suppl 1():127-33. PubMed ID: 9422098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
